Myasthenia gravis is an autoimmune disease resulting from a breakdown in T and B cell tolerance to acetylcholine receptor (AChR). Autoantibodies to AChR mediate the disease. Recent advances in experimental immunotherapy of autoimmune disease provide several possibilities for specific intervention in this well‐characterized condition.—S teinman , L.; M antegazza , R. Prospects for specific immunotherapy in myasthenia gravis. FASEB J. 4: 2726‐2731; 1990.
No takes yet. Share an insight, caveat, or question.
Steinman et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: